Condie Carmack, PhD

Dr. Condie Carmack is a distinguished molecular biologist
with a PhD in Experimental Pathology from the University of Utah. Following his doctorate, he undertook post-doctoral fellowships with notable scientists such as Randy Hardy and Kyoko Hayakawa at the Fox Chase Cancer Center in Philadelphia, and later with Roy Riblet in San Diego, California.

While at Fox Chase, Dr. Carmack pioneered the first
quantitative PCR method, well ahead of the introduction of TaqMan. Subsequently, he became an integral part of GenPharm International, contributing to the development of the world’s first transgenic mouse designed for producing human monoclonal antibodies. Notably, these mice played a crucial role for Dr. Jim
Allison in the creation of ipilimumab and other groundbreaking Immuno-Oncology treatments.

Dr. Carmack’s vast experience also includes pivotal roles at
Molecular Dynamics, where he delved into the intricacies of microarrays — a revolutionary technology of its time. His journey further led him to esteemedinstitutions such as Agilent, Loxo@Lilly, Vela, NuGen, and the Baylor College of Medicine.